Biopharma Daily Stock Updates - 05/04/21

$XBI $129.81 -4%

Pipeline Updates

$CCXI -43% Adcom briefing docs released. source


$BLRX +52% Positive ph 3 GENESIS results of Motixafortide + G-CSF for multiple myeloma. source


$VXRT +4% First patient enrolled in ph1b Norovirus study. source


$SIGA +1% submits NDA for TIPOXX for smallpox. source


$CYTK -6% Ph 2 cohort 3 of REDWOOD-HCM open for enrollment. source


$CMPI -4% Initiated ph 2 combo study of Vido + Nivo. source


$OBSV +2% Completed enrollment for the Phase 3 EDELWEISS 3 trial of Yeslty® (linzagolix) for patients with moderate to severe endometriosis-associated pain (EAP). Data from the primary endpoint readout are expected in Q4 2021. source


Financial Updates

$COCP +52% $40M bought deal offering w/ HC Wainwright @ $1.54/sh. source


$ESPR -24% Revenue miss. source


$ATNX +20% to acquire Kuur Tx, terms include $70M upfront, and $115M of milestone payments, as cash or ATNX stock. source


$IBIO +27% settled lawsuit with Fraunhofer USA, IBIO receives payments and Fraunhofer USA license to use recombinant protein manufacturing technology. source


$PRQR -8% Yarrow bio in-licensed ASO tech to develop therapy for undisclosed target. source


0 comments